JeanMarie Guenot is the president and CEO of Amphivena Therapeutics. This is an organization that aims at restoring life to the cancer patients by eradicating the cancer cells while strengthening a patient’s own immune system.
According to CrunchBase, JeanMarie Guenot studied Physical and Medical chemistry specializing in protein structure prediction, X-ray and NMR confinement, quantum mechanical and semi-empirical methods for molecular dynamics and drug design. She has a Ph.D. from the University of San Francisco, California and An MBA from Wharton School, University of Pennsylvania.
She has over 20 years of working experience in both private and public companies in different roles. She started her career as an entrepreneur in Atlas ventures where she managed capital investments and played a role in building life science companies. Her medical/ scientific career started at Hoffmann-La ROCHE where she was the principal scientist in charge of developing of drugs that cure autoimmune diseases, inflammation, metabolic diseases and oncology. Before moving to Amphivena Therapeutics, she founded the SKS Ocular. This an ophthalmic company that releasing ocular drug delivery techniques as well as ocular inflammation and mass degeneration.
At Amphivena Therapeutics, JeanMarie Guenot leads a host of other equal professionals in the medical field to do research and develop antibody therapy to address blood cancer. Starting its operation in July 2013, the firm has partnered with other institutions that are passionate and interested in the therapy of passionate by bringing on board their expertise, experience, and academic qualifications. Their latest research led to the discovery of Vitro and in vivo killing of AML using tetravalent bispecific CD33/CD3 TandAbs in May 2015.
As a woman who has accomplished so much both as an entrepreneur and in the medical fraternity, she is indeed a female role model to the whole world. In 2005, she was awarded Bio Business Network Innovative Bio-Partnering and in 2006, she was awarded for a deal of distinction from the Licensing Executive Society. She is a hard worker and her professional skills have made her succeed both in her work and in life in general. Her most notable achievement, however, will be the 50:50 deal she made between Hoffman-La Roche and PLD to develop and commercialize their drugs.